Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence | Zendy

Tanou Kalliopi | Zendy; Zintzaras Elias | Zendy; Kaditis Athanasios G. | Zendy

Premium

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence

Author(s) -

Tanou Kalliopi,

Zintzaras Elias,

Kaditis Athanasios G.

Publication year - 2014

Publication title -

pediatric pulmonology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.866

H-Index - 106

eISSN - 1099-0496

pISSN - 8755-6863

DOI - 10.1002/ppul.22937

Subject(s) - medicine , allergic bronchopulmonary aspergillosis , cystic fibrosis , omalizumab , immunoglobulin e , aspergillosis , aspergillus fumigatus , immunology , dermatology , antibody

Summary Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti‐IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti‐IgE resulting in improved FEV 1 , fewer respiratory symptoms and decreased corticosteroid use. Pediatr Pulmonol. 2014; 49:503–507. © 2013 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research